 |
12 Diseases |  |
17 Trials |
|
17 Trials |  |
2487 News |  |
| «12...910111213141516171819...2425» |
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: One year experience with erenumab: real-life data in 30 consecutive patients. (Pubmed Central) - May 15, 2021
No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Efficacy of erenumab 70 mg in chronic migraine: Vicenza experience. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: A longitudinal clinical and MRI evaluation of the treatment with erenumab. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Erenumab efficacy in highly resistant chronic migraine: a real-life study. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- | Aimovig (erenumab) / Amgen, Novartis
Journal: Migraineurs' psychological traits do not influence response to erenumab. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Observational data, Journal: Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Exploring new strategy in erenumab therapy for migraine patients. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Observational data, Journal: Effectiveness of erenumab in chronic migraine patients with associated medication overuse headache: a prospective observational study. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Efficacy and safety of erenumab in the real-life setting of S. Antonio Abate Hospital's Headache Center (Gallarate). (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Erenumab during pregnancy: a case report in a patient with chronic migraine. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- || Aimovig (erenumab-aooe) / Amgen, Novartis
New P2 trial: Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (clinicaltrials.gov) - May 12, 2021
P2, N=30, Not yet recruiting, Sponsor: Indiana University
- ||||| Aimovig (erenumab) / Amgen, Novartis
Clinical: The goal of this @GreenJournal study by Dr. Peter Goadsby @petergoadsby was to evaluate the efficacy of erenumab among certain episodic #migraine patients of the #LIBERTY study. https://t.co/mJjytM6f9g (Twitter) - May 7, 2021
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Biomarker, Trial completion date, Trial primary completion date: INTERROGATE: Biomarker and Genetic Predictors of Erenumab Treatment Response (clinicaltrials.gov) - May 6, 2021
P4, N=2000, Recruiting, Sponsor: Amgen
No abstract available Trial completion date: Apr 2022 --> Dec 2022 | Trial primary completion date: Apr 2022 --> Dec 2022
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine (clinicaltrials.gov) - May 3, 2021
P4, N=29, Active, not recruiting, Sponsor: Amgen
Trial completion date: Apr 2022 --> Dec 2022 | Trial primary completion date: Apr 2022 --> Dec 2022 Recruiting --> Active, not recruiting | N=340 --> 29 | Trial completion date: Nov 2022 --> Jul 2021 | Trial primary completion date: Nov 2022 --> Jul 2021
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: Effectiveness of a Health Education Programme for Prevention of Chronic Migraine: A Randomized Clinical Trial (clinicaltrials.gov) - May 2, 2021
P=N/A, N=182, Recruiting, Sponsor: Universidad de Zaragoza
Recruiting --> Active, not recruiting | N=340 --> 29 | Trial completion date: Nov 2022 --> Jul 2021 | Trial primary completion date: Nov 2022 --> Jul 2021 Not yet recruiting --> Recruiting
- || Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Review, Journal: A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. (Pubmed Central) - Apr 30, 2021
Most of the observed heterogeneity is ascribed to treatment duration for back pain (p = 0.045), influenza (p < 0.001) and URTI (p < 0.001), and significantly attributed to Body Mass Index (BMI) for nasopharyngitis (p < 0.001). Back pain, influenza, nasopharyngitis and URTI showed a significant heterogeneity of incidence estimates.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Long-Term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study. (Pubmed Central) - Apr 30, 2021
P3
In patients with EM who were unsuccessful on 2-4 prior preventive treatments, the LIBERTY study demonstrated sustained efficacy on erenumab monotherapy treatment through 64 weeks in both treatment arms. Safety of erenumab was consistent with that observed in previous clinical trials.
- || Review, Journal: Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels. (Pubmed Central) - Apr 30, 2021
Major classes of membrane-associated protein targets include G protein-coupled receptors (GPCRs) and ion channels that are linked to a wide range of disease indications across all therapeutic areas. This mini-review summarizes the antibody target landscape for both GPCRs and ion channels as well as current progress in the respective research and development pipelines with some example case studies highlighted from clinical studies, including those being evaluated for the treatment of symptoms in COVID-19 infection.
- ||||| Aimovig (erenumab) / Amgen, Novartis
Clinical: Also interesting evidence of CGRP involvement in raised ICP headache, with papilloedema recurring in patients but no recurrence of headache on erenumab treatment @IIHDrBirmingham @abnconf @DrAndreasY read more: https://t.co/EoZ48WgMrO @EHF_Official (Twitter) - Apr 29, 2021
- ||| Journal, Adverse events: Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain. (Pubmed Central) - Apr 29, 2021
This mini-review summarizes the antibody target landscape for both GPCRs and ion channels as well as current progress in the respective research and development pipelines with some example case studies highlighted from clinical studies, including those being evaluated for the treatment of symptoms in COVID-19 infection. The different safety profile of treatment with fremanezumab, compared to erenumab, galcanezumab, and onabotulinumtoxinA, would generate savings in health-care resources in all the scenarios considered.
- ||| Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal, Adverse events: New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database. (Pubmed Central) - Apr 29, 2021
Adverse events reported during the first 2 years of post-marketing surveillance were mostly non-serious and with a favorable prognosis. However, new safety aspects emerged for which further studies are needed to confirm the associations, prioritizing unlabeled events with consistent disproportionality signals (e.g., emerging in at least 4 out of 6 analyses).
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial initiation date: MicroRNA Profile and Erenumab Treatment (clinicaltrials.gov) - Apr 27, 2021
P=N/A, N=40, Not yet recruiting, Sponsor: University of L'Aquila
However, new safety aspects emerged for which further studies are needed to confirm the associations, prioritizing unlabeled events with consistent disproportionality signals (e.g., emerging in at least 4 out of 6 analyses). Trial completion date: Apr 2022 --> Jul 2022 | Initiation date: Jan 2021 --> Jun 2021
- || Botox (onabotulinumtoxin A) / GSK, AbbVie, Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine. (Pubmed Central) - Apr 27, 2021
Moreover, the combined therapy with BTX-A and erenumab resulted in a statistically significant reduction in the symptomatic drug intake and in migraine-related disability probably related to a reduced necessity or also to a better responsiveness to rescue treatments. Present data suggest a remodulation of current provisions depriving patients of an effective therapeutic strategy in peculiar migraine endophenotypes.
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: RESET BRAIN: A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients (clinicaltrials.gov) - Apr 22, 2021
P4, N=62, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Present data suggest a remodulation of current provisions depriving patients of an effective therapeutic strategy in peculiar migraine endophenotypes. Trial primary completion date: Feb 2021 --> Jun 2021
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine (clinicaltrials.gov) - Apr 22, 2021
P=N/A, N=40, Recruiting, Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation
Trial primary completion date: Feb 2021 --> Jun 2021 Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: Erenumab For Treatment of Hemicrania Continua (clinicaltrials.gov) - Apr 22, 2021
P2, N=20, Not yet recruiting, Sponsor: Mayo Clinic
Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Retrospective data, Journal, HEOR: Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study. (Pubmed Central) - Apr 22, 2021
In this retrospective analysis, erenumab was associated with significantly reduced acute medication use and HCRU in a real-world setting, hence significantly reducing the burden of the disease. A composite endpoint could be used as a proxy to evaluate the burden of migraine attacks; however, further research is needed.
- || Botox (onabotulinumtoxin A) / GSK, AbbVie
Retrospective data, Review, Journal, HEOR, Real-world evidence: Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. (Pubmed Central) - Apr 22, 2021
In this real-world study, combination treatment with onabotulinumtoxinA and CGRP mAbs was well tolerated, with no new safety signals identified, and was associated with additional clinically meaningful benefits. More real-world and controlled trials should be considered to further assess safety and potential benefits of combination treatment.
- || Clinical, Retrospective data, Review, Journal: Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis. (Pubmed Central) - Apr 21, 2021
Most drugs performed similarly and were superior to placebo in most of our analyses. Further head-to-head research on different types of CGRP monoclonal antibodies is necessary to validate the present findings.
- | Aimovig (erenumab) / Amgen, Novartis
Journal: In brief: Hypertension with erenumab (Aimovig). (Pubmed Central) - Apr 20, 2021
Further head-to-head research on different types of CGRP monoclonal antibodies is necessary to validate the present findings. No abstract available
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real-world evidence for control of patients with chronic migraine who received calcitonin generelated peptide (CGRP) monoclonal antibody therapy added to onabotulinumtoxinA treatment () - Apr 17, 2021 - Abstract #AMCP2021AMCP_320;
Combination therapy was well tolerated with no new safety signals identified. More real-world studies and controlled trials are needed to further quantify potential benefits of this multimodal treatment paradigm.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Clinical data, Review, Journal, HEOR, Real-world evidence: Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers. (Pubmed Central) - Apr 16, 2021
In this predominantly refractory chronic migraine population treated in select headache centers, patients had fewer headache/migraine days per month and outpatient visits after initiating erenumab. However, patients largely continued to be managed via a polypharmacy approach after erenumab initiation.
- Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] MATCHING-ADJUSTED INDIRECT COMPARISONS OF INTERMITTENT ORAL RIMEGEPANT VERSUS PLACEBO AND INJECTABLE ANTI-CGRP-TARGETED MONOCLONAL ANTIBODIES EXAMINING MONTHLY MIGRAINE DAYS IN THE TREATMENT OF MIGRAINE () - Apr 11, 2021 - Abstract #AMCP2021AMCP_103;
Oral rimegepant was found to be superior to placebo and comparable to injectable galcanezumab and erenumab in reducing MMD. While a controlled trial would be the optimal methodology for assessing relative difference, the available data demonstrate that rimegepant may be effective in the prevention of migraine.
- || Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo
Clinical, Review, Journal: The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions. (Pubmed Central) - Apr 7, 2021
Furthermore, its safety profile, especially its potential association with an increased cardiovascular risk, needs to be established through long-term, real-world data. This review aims to give an overview of its pharmacological properties as well as to report and discuss data from clinical trials and its potential place in headache therapeutics.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series. (Pubmed Central) - Apr 7, 2021
This review aims to give an overview of its pharmacological properties as well as to report and discuss data from clinical trials and its potential place in headache therapeutics. Our data suggest that migraine is more frequent during than outside menstrual days even in women treated with erenumab.
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Evaluating The Efficacy and Safety of Switching from Onabotulinum Toxin Type A to Erenumab-aooe during COVID-19 () - Apr 4, 2021 - Abstract #CPNP2021CPNP_175;
Outcomes: We will report average number of headaches per month and average severity of headaches between patients who received onabotulinum toxin A and erenumab-aooe. We will also compare the number of headaches per month between patients who continued with erenumab-aooe versus those who switch back to onabotulinum toxin A.
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] A Comparison of Erenumab versus Botulinum among Veterans with Chronic Migraines in the setting of COVID-19 () - Apr 4, 2021 - Abstract #CPNP2021CPNP_147;
This project was submitted to the local Research Office for approval as a quality assessment/quality improvement project. Outcomes: Data for this project is still undergoing evaluation, and trends noted during analysis may be used to modify local clinical practices as needed.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Review, Journal: Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review. (Pubmed Central) - Apr 1, 2021
In one trial, decreases in monthly migraine days were -1.8 after placebo, -3.2 after erenumab 70 mg and -3.7 after erenumab 140 mg, with the ordinate stopped at -4.5...Such figures, presenting persisting MMDs, are more clinically relevant and less misleading than decreases from baseline. The definition and methods of calculating and presenting "50% response rates" should be standardized by the Drug Trial Committee of the International Headache Society.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response. (Pubmed Central) - Apr 1, 2021
P2
For erenumab-treated patients achieving ≥50% response, the actual reduction in MMD was almost twice that of the overall population. These findings provide context for setting realistic expectations regarding actual treatment benefit experienced by patients responding to treatment.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P4 trial: A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine (clinicaltrials.gov) - Apr 1, 2021
P4, N=322, Not yet recruiting, Sponsor: Amgen
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: EMBRACE: Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine (clinicaltrials.gov) - Mar 24, 2021
P4, N=576, Recruiting, Sponsor: Amgen
These findings provide context for setting realistic expectations regarding actual treatment benefit experienced by patients responding to treatment. Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Calcitonin Gene-Related Peptide Inhibitor Use for Migraine Associated with Exacerbation of Raynaud Phenomenon () - Mar 18, 2021 - Abstract #AAN2021AAN_2760;
Our results indicate that microvascular complications of CGRP antagonist use in patients with underlying RP are uncommon (5.3%). The incidence of serious adverse events, although rare, warrant caution when considering the use of these agents in patients with RP.
- [VIRTUAL] Industry payments in Neurology Subspecialties: 2014 - 2018 () - Mar 18, 2021 - Abstract #AAN2021AAN_2057;
The introduction of newer medications in a subspecialty coincided with higher industry payments. Identification of these trends and potential motives of the industry spending is critical to address any potential physician bias in prescribing medications.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Acute Onset of Thrombotic Thrombocytopenic Purpura after Erenumab Treatment: A Case Report () - Mar 18, 2021 - Abstract #AAN2021AAN_1149;
Although we cannot exclude the possibility of idiopathic TTP, the close temporal association with treatment onset suggests a causative link. Further monitoring and study are necessary to determine the absolute risk of this and other potential complications from erenumab therapy.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Treatment of Patients with Concussion () - Mar 18, 2021 - Abstract #AAN2021AAN_1148;
There was a subset of patients with a more robust response. Switching anti-CGRP mAbs was beneficial in some patients.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Single Center Experience of mAbs-CGRP Use for Migraine Prevention () - Mar 18, 2021 - Abstract #AAN2021AAN_1141;
Reasons for stopping included medication failure, adverse effects, and insurance difficulties. Combined use of mAb and OnabotulinumbtoxinA seemed to be a safe and efficacious treatment of migraine.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Real-world Adherence, Persistence, Switching, and Reinitiation in Patients Prescribed AJOVY in US Physician Practices () - Mar 18, 2021 - Abstract #AAN2021AAN_1134;
Combined use of mAb and OnabotulinumbtoxinA seemed to be a safe and efficacious treatment of migraine. Real-world treatment adherence and persistence were high with AJOVY; the majority of patients who discontinued AJOVY treatment discontinued any treatment or switched to a different preventive treatment class, and several patients restarted AJOVY.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Discrete Choice Experiment to Understand Patient Preferences for Self-Injectable Preventive Treatments for Migraine – A quantitative pilot () - Mar 18, 2021 - Abstract #AAN2021AAN_1131;
Patients preferred a profile similar to galcanezumab over profiles of other self-injectable migraine preventive treatments. The preference information may enhance communication about potentially effective migraine preventive treatment options.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Design and Population characteristics of patients treated with monoclonal antibody erenumab for assessment of long-term safety and tolerability and frequency of drug holidays in Germany (APOLLON) () - Mar 18, 2021 - Abstract #AAN2021AAN_1063;
P4
This analysis will provide insights into the patient population enrolled in the APOLLON study to assess long-term safety and tolerability of erenumab. Furthermore, common treatment algorithms will be elucidated by investigating the impact of drug holidays during prophylactic migraine treatment in the participating 80 headache centers in Germany.